Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma (Q36611899)

15 August 2017

Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma (English)

1 reference

15 August 2017

1 reference

R Maruyama

1

1 reference

15 August 2017

K Yamana

2

1 reference

15 August 2017

T Itoi

3

1 reference

15 August 2017

N Hara

4

1 reference

15 August 2017

V Bilim

5

1 reference

15 August 2017

T Nishiyama

6

1 reference

15 August 2017

K Takahashi

7

1 reference

15 August 2017

Y Tomita

8

1 reference

15 August 2017

language of work or name

English

0 references

publication date

10 October 2006

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

95

1 reference

15 August 2017

9

1 reference

15 August 2017

1244-1249

1 reference

Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360577

Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360577

Analysis of Fas gene mutations on laser capture microdissected specimens from renal cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360577

Death receptors couple to both cell proliferation and apoptosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360577

The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360577

The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360577

Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360577

Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360577

Frequent expression of Bcl-2 in renal-cell carcinomas carrying wild-type p53.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360577

Expression of intercellular adhesion molecule-1 on transitional cell cancer. Possible significance in immunity against tumor cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360577

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360577

Downregulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360577

Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360577

Impact of histology on the treatment outcome of metastatic or recurrent renal cell carcinoma

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360577

Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360577

APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360577

Loss of anti-mitotic effects of Bcl-2 with retention of anti-apoptotic activity during tumor progression in a mouse model

20 September 2018

1 reference

12 December 2020

Role of IRF-1 and caspase-7 in IFN-gamma enhancement of Fas-mediated apoptosis in ACHN renal cell carcinoma cells

1 reference

12 December 2020

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma

1 reference

12 December 2020

Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness

1 reference

12 December 2020

Deletion of a nonconserved region of Bcl-2 confers a novel gain of function: suppression of apoptosis with concomitant cell proliferation

1 reference

12 December 2020

Tetrapeptide DEVD-aldehyde or YVAD-chloromethylketone inhibits Fas/Apo-1(CD95)-mediated apoptosis in renal-cell-cancer cells

1 reference

12 December 2020

Fas/APO-1-mediated apoptosis of human renal cell carcinoma

1 reference

12 December 2020

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

12 December 2020

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response

1 reference

12 December 2020

Bcl-2 modulates Fas-mediated apoptosis in human renal cell carcinoma cell lines

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6603359

1 reference

release_zeekvmktnfcs7n23ymbfq7svdm

15 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zeekvmktnfcs7n23ymbfq7svdm

24 November 2022

mapped directly with Wikidata item

1 reference

15 August 2017

PubMed publication ID

17031406

1 reference